Rociletinib is a third generation EGFR inhibitor that in a phase I/II trial has demonstrated efficacy in patients with EGFR-mutant non-small cell lung cancer with the T790M resistance mutation who progressed on standard anti-EFGR treatment [93]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.